

### Glanbia plc Transaction in Own Shares

Thursday, April 18, 2024 Glanbia plc ("Glanbia" or the "Company"), the Better Nutrition company, announces that on Wednesday, April 17, 2024 it purchased the following number of its ordinary shares (the "Ordinary Shares") on Euronext Dublin, via Glanbia's broker J&E Davy. The Ordinary Shares purchased will be cancelled.

	Euronext Dublin
Number of Ordinary Shares purchased:	46,000
Highest price paid per Ordinary Share:	€17.6300
Lowest price paid per Ordinary Share:	€17.5500
Volume weighted average price paid per Ordinary Share:	€17.5752

The Ordinary Shares purchased form part of Glanbia's intention to buy back the Company's Ordinary Shares of a total value of up to €50 million in the period up to 19 December 2024 ("**Buy-Back Programme**"). This Buy-Back Programme was announced on 28 February 2024 and formally commenced on that date.

Following settlement of the above transactions and subsequent share cancellation Glanbia will hold 263,557,750 ordinary shares in issue.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), a detailed breakdown of individual trades made by Davy on behalf of Glanbia as part of the buyback programme is scheduled to this announcement.

Contact:  
Liam Hennigan  
Group Secretary and Head of Investor Relations  
Tel: + 353 86 046 8375

Olivia Kennington  
Deputy Group Secretary  
Tel: + 35356 777 2200

Issuer name:	Glanbia plc
LEI	635400SRMCBHVMSKJS84
ISIN:	IE0000669501
Intermediary name:	J&E Davy
Intermediary code:	DAVYIE21
Time zone:	GMT
Currency:	EUR

### Aggregated Information

Trading venue	Currency	Volume Weighted Average Price	Aggregated volume
Euronext Dublin	EUR	17.5752	46,000

## Euronext Dublin

Number of Shares	Price per Share (EUR)	Trading Venue	Time of Transaction	MatchId
8000	17.63	Euronext Dublin	09:39:43	00042284656TRLOO-1
26000	17.57	Euronext Dublin	14:51:52	00042287479TRLOO-1
12000	17.55	Euronext Dublin	15:48:04	00042288322TRLOO-1

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

POBLGDSLBBGSR